COVID-19 Omicron Vaccine
This is a research study looking for people between the ages of 18 to 64 to participate in a research study for a new protein-based COVID-19 vaccine based on the omicron variant. Some vaccines that were developed against the original form of the virus have been shown to be less effective in protecting against mild disease caused by the new Omicron variant.
This study will evaluate whether this new COVID-19 booster vaccine will provide greater protection against COVID infection with the variant. In the study, you will either receive the new COVID-19 vaccine or a current COVID-19 vaccine.
The study will run over approximately a 10-month period and would require approximately 10 visits to the study site. Visits will range between 15 mins to an hour. Over the course of the study, we will check your medical history, take blood samples and administer the new COVID-19 vaccine or a current vaccine. You will also be asked to record symptoms on an electronic diary for the duration of the study after administration of the vaccine.
You will be reimbursed for your time and involvement in the research study.
- Aged between 18 and 64
- Has received either two or three doses of Pfizer or Moderna COVID-19 vaccine
- Is not immunocompromised